Dianthus Therapeutics stock
DNTHNASDAQDianthus Therapeutics, Inc., HealthcareISIN US2528281080
46Score 46 out of 100, Weak
Price and trend
72 / 100
Price history
+139% in one yearThe chart shows daily closes over 8 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 6.6% above it.
Since September 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 82).
The price is 20% below its 52-week high. Largest decline in 8 years: 98% (March 2019 to December 2022).
Chart figures for advanced users
- SMA 50$88.77
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$86.73
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)82
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$35.50
- The lowest closing price of the last twelve months.
- Resistance$115.96
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Dianthus Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $5.21B, is number 72 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.04M (down 67.3% year on year) and a loss of $162.34M.
- For fiscal 2026, analysts expect on average revenue of $2.52M (up 23.8%) and adjusted earnings per share of −$3.54.
Show more
- MEQIRI Score 46 out of 100 (Weak): rank 435 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $837.78M, financial debt $1.21M.Stability 73
Weaknesses
- Loss-makingLoss of $39.79M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$175.85M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 61% a year over the last 12 months.
Its standout strengths are momentum and stability, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue fell 67.3% on the prior year. Revenue turned from negative at the start of the period to positive ($2.04M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 100%, operating −8739%, net −7973%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 8 Mar 2027in 115 days
- Last reported
- 4 Nov 2026EPS reported −$0.81 (expected −$0.94)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 6.6% since 15 Oct 2026.
- Earnings per share
- −$3.54+6.6%
- Revenue
- $2.52M+34.0%
- Earnings per share
- −$4.33+5.4%
- Revenue
- $2.3M+13.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 7 insiders sold, $45.33M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Savitz RyanSale
12 Nov 2026, EVP, CFO & CBO
- Shares
- 17,724
- Price
- $90.56
- Value
- $1.61M
- Savitz RyanSale
11 Nov 2026, EVP, CFO & CBO
- Shares
- 3,044
- Price
- $90.03
- Value
- $274,051
- Savitz RyanSale
10 Nov 2026, EVP, CFO & CBO
- Shares
- 2,561
- Price
- $90.14
- Value
- $230,849
Show 12 more
- Savitz RyanSale
9 Nov 2026, EVP, CFO & CBO
- Shares
- 100,713
- Price
- $90.54
- Value
- $9.12M
- Carr EdwardSale
17 Sept 2026, CHIEF ACCOUNTING OFFICER
- Shares
- 20,000
- Price
- $101.38
- Value
- $2.03M
- Randhawa SimratSale
1 Sept 2026, EVP, Head of R&D
- Shares
- 23,124
- Price
- $106.41
- Value
- $2.46M
- Read SimonSale
19 Aug 2026, Board
- Shares
- 2,778
- Price
- $117.55
- Value
- $326,554
- McGeorge AnneSale
10 Aug 2026, Board
- Shares
- 7,750
- Price
- $109.01
- Value
- $844,822
- Read SimonSale
10 Aug 2026, Board
- Shares
- 2,777
- Price
- $109.55
- Value
- $304,232
- Veness Adam MSale
10 Aug 2026, SVP, General Counsel and Sec.
- Shares
- 16,167
- Price
- $110.38
- Value
- $1.78M
- Veness Adam MSale
7 Aug 2026, SVP, General Counsel and Sec.
- Shares
- 3,833
- Price
- $110.70
- Value
- $424,319
- Garcia MarinoSale
7 Aug 2026, CEO AND PRESIDENT
- Shares
- 166,000
- Price
- $108.11
- Value
- $17.95M
- Savitz RyanSale
9 Jul 2026, EVP, CFO & CBO
- Shares
- 31,249
- Price
- $101.03
- Value
- $3.16M
- Veness Adam MSale
17 Jun 2026, SVP, General Counsel and Sec.
- Shares
- 30,000
- Price
- $80.80
- Value
- $2.42M
- Randhawa SimratSale
1 Jun 2026, EVP, Head of R&D
- Shares
- 26,530
- Price
- $90.62
- Value
- $2.4M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Dianthus Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 46
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Anthem BiosciencesANTHEM.NS $5.62B78
- Shanghai Allist Pharmaceuticals688578.SS $5.61B66
- ErascaERAS $5.52B44
- PTC TherapeuticsPTCT $5.29B46
- SK Biopharmaceuticals326030.KS $5.14B67
- Cogent BiosciencesCOGT $5.07B28
- Travere TherapeuticsTVTX $4.95B50
- Edgewise TherapeuticsEWTX $4.93B54
ETFs that hold Dianthus Therapeutics
Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.44% | 0.40% | €1.5B |
| iShares Ageing Population UCITS ETF2B77 | 0.41% | 0.40% | €813.42M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.14% | 0.30% | €2.22B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.14% | 0.30% | €4.28B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.11% | 0.30% | €185.82M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.05% | 0.43% | €2.5B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.03% | 0.45% | €1.54B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.03% | 0.10% | €395.74M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2019)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.